GTC Biotherapeutics (fka GTCB)

[Pre_Clinical]

<<<<
Expression level is a separate issue from glycosylation variants. (The latter is a red herring, IMO.)
<<<<<<<

You can think that all you want, but show me the data to support your point. All that Ive asked (rather politely mind you) is to see a table of proteins produced both in goat milk and CHO cells demonstrating bioequivalent PK/PD. What we do know is that for the company's lead protein, Atryn, the in-vivo half-life is shorter than the dominant form found in plasma. This was due to a difference in glycosylation state. So the question is, how common is this, and to what degree does the mammary gland glycosylation pathway differ from other expression systems, in particular CHO cells?

And sorry, quotes from mgmt that say, "Dont worry" aint gonna cut it.